Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 194

1.

Efficacy and safety of sodium oxybate in alcohol-dependent patients with a very high drinking risk level.

van den Brink W, Addolorato G, Aubin HJ, Benyamina A, Caputo F, Dematteis M, Gual A, Lesch OM, Mann K, Maremmani I, Nutt D, Paille F, Perney P, Rehm J, Reynaud M, Simon N, Söderpalm B, Sommer WH, Walter H, Spanagel R.

Addict Biol. 2018 Jul;23(4):969-986. doi: 10.1111/adb.12645.

PMID:
30043457
2.

Cannabis and opioid overdoses: time to move on and examine potential mechanisms.

Rogeberg O, Blomkvist AW, Nutt D.

Addiction. 2018 Aug;113(8):1551-1552. doi: 10.1111/add.14238. Epub 2018 Jun 7. No abstract available.

PMID:
29882246
3.

Towards earlier diagnosis and treatment of disorders of the brain.

Di Luca M, Nutt D, Oertel W, Boyer P, Jaarsma J, Destrebecq F, Esposito G, Quoidbach V.

Bull World Health Organ. 2018 May 1;96(5):298-298A. doi: 10.2471/BLT.17.206599. No abstract available.

4.

Imaging and Genetic Approaches to Inform Biomarkers for Anxiety Disorders, Obsessive-Compulsive Disorders, and PSTD.

Maron E, Lan CC, Nutt D.

Curr Top Behav Neurosci. 2018 May 24. doi: 10.1007/7854_2018_49. [Epub ahead of print]

PMID:
29796838
5.

Correction to: The hidden therapist: evidence for a central role of music in psychedelic therapy.

Kaelen M, Giribaldi B, Raine J, Evans L, Timmermann C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R.

Psychopharmacology (Berl). 2018 May;235(5):1623. doi: 10.1007/s00213-018-4886-8.

6.

A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.

Rogeberg O, Bergsvik D, Phillips LD, van Amsterdam J, Eastwood N, Henderson G, Lynskey M, Measham F, Ponton R, Rolles S, Schlag AK, Taylor P, Nutt D.

Int J Drug Policy. 2018 Jun;56:144-152. doi: 10.1016/j.drugpo.2018.01.019. Epub 2018 Feb 17.

7.

Psychedelics and related drugs: therapeutic possibilities, mechanisms and regulation.

Curran HV, Nutt D, de Wit H.

Psychopharmacology (Berl). 2018 Feb;235(2):373-375. doi: 10.1007/s00213-017-4822-3. No abstract available.

PMID:
29445838
8.

The hidden therapist: evidence for a central role of music in psychedelic therapy.

Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R.

Psychopharmacology (Berl). 2018 Feb;235(2):505-519. doi: 10.1007/s00213-017-4820-5. Epub 2018 Feb 2. Erratum in: Psychopharmacology (Berl). 2018 Mar 26;:.

9.

A point mutation in the ion conduction pore of AMPA receptor GRIA3 causes dramatically perturbed sleep patterns as well as intellectual disability.

Davies B, Brown LA, Cais O, Watson J, Clayton AJ, Chang VT, Biggs D, Preece C, Hernandez-Pliego P, Krohn J, Bhomra A, Twigg SRF, Rimmer A, Kanapin A; WGS500 Consortium, Sen A, Zaiwalla Z, McVean G, Foster R, Donnelly P, Taylor JC, Blair E, Nutt D, Aricescu AR, Greger IH, Peirson SN, Flint J, Martin HC.

Hum Mol Genet. 2017 Oct 15;26(20):3869-3882. doi: 10.1093/hmg/ddx270.

10.

Is the UK's 2017 drug strategy fit for purpose?

Ford C, Nutt D, Eastwood N, Gold D, Jolly J, Murphy F, Halliday K, Bridge J.

BMJ. 2017 Sep 29;358:j4405. doi: 10.1136/bmj.j4405. No abstract available.

PMID:
28963111
11.

Biological markers of generalized anxiety disorder.

Maron E, Nutt D.

Dialogues Clin Neurosci. 2017 Jun;19(2):147-158. Review.

12.

A Brief Outline of the Use of New Technologies for Treating Substance Use Disorders in the European Union.

Quaglio G, Schellekens A, Blankers M, Hoch E, Karapiperis T, Esposito G, Brand H, Nutt D, Kiefer F.

Eur Addict Res. 2017;23(4):177-181. doi: 10.1159/000478904. Epub 2017 Aug 12.

PMID:
28803249
13.

New ACMD regulations threaten UK's pharmaceutical discovery.

Nutt D.

Lancet. 2017 Jun 10;389(10086):2283. doi: 10.1016/S0140-6736(17)31461-7. No abstract available.

PMID:
28612742
14.

A Plutocratic Proposal: an ethical way for rich patients to pay for a place on a clinical trial.

Masters A, Nutt D.

J Med Ethics. 2017 Nov;43(11):730-736. doi: 10.1136/medethics-2016-104050. Epub 2017 Jun 6.

15.

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight.

Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R.

Lancet Psychiatry. 2017 May;4(5):419-426. doi: 10.1016/S2215-0366(17)30102-5. Epub 2017 Apr 5. Review.

PMID:
28395988
16.

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

Quelch DR, Mick I, McGonigle J, Ramos AC, Flechais RSA, Bolstridge M, Rabiner E, Wall MB, Newbould RD, Steiniger-Brach B, van den Berg F, Boyce M, Østergaard Nilausen D, Breuning Sluth L, Meulien D, von der Goltz C, Nutt D, Lingford-Hughes A.

Biol Psychiatry. 2017 Jun 1;81(11):941-948. doi: 10.1016/j.biopsych.2016.12.029. Epub 2017 Jan 10.

PMID:
28216062
17.

Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development.

Shimshoni JA, Winkler I, Edery N, Golan E, van Wettum R, Nutt D.

Toxicol Appl Pharmacol. 2017 Mar 15;319:59-68. doi: 10.1016/j.taap.2017.01.018. Epub 2017 Feb 4.

PMID:
28167221
18.

Neural substrates of cue reactivity and craving in gambling disorder.

Limbrick-Oldfield EH, Mick I, Cocks RE, McGonigle J, Sharman SP, Goldstone AP, Stokes PR, Waldman A, Erritzoe D, Bowden-Jones H, Nutt D, Lingford-Hughes A, Clark L.

Transl Psychiatry. 2017 Jan 3;7(1):e992. doi: 10.1038/tp.2016.256.

19.

Inverse agonists - What do they mean for psychiatry?

Nutt D, Stahl S, Blier P, Drago F, Zohar J, Wilson S.

Eur Neuropsychopharmacol. 2017 Jan;27(1):87-90. doi: 10.1016/j.euroneuro.2016.11.013. Epub 2016 Dec 7.

20.

Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future.

Nutt D.

J Psychopharmacol. 2016 Dec;30(12):1163-1164. No abstract available.

PMID:
27909163

Supplemental Content

Loading ...
Support Center